Atrium Therapeutics Receives FDA Clearance for ATR 1072 IND
Atrium Therapeutics obtained FDA clearance to launch the Phase 1/2 Corventis trial for the precision cardiology candidate ATR 1072. This regulatory milestone validates the company's approach to treating rare genetic cardiomyopathies.
View filing at SEC.gov →